Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	5	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	12	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS	13	SEP 27	STANDARDS will no longer be available on STN
NEWS	14	SEP 27	SWETSCAN will no longer be available on STN
NEWS	15	SEP 30	STN downtime scheduled October 2-3, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:29:06 ON 03 OCT 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:29:12 ON 03 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2
DICTIONARY FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l1
NO L# DEFINED

There are no L# queries, structures, or screen sets defined in the current session.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\STNEXP4\QUERIES\10632340.str



chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22
chain bonds :
4-13 6-7 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-18
15-16 15-19 16-17 16-22 17-18 19-20 20-21 21-22
exact/norm bonds :
4-13 6-7 13-14 14-15 14-18 15-16 15-19 16-17 16-22 17-18 19-20 20-21
21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:29:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     14 TO ITERATE

100.0% PROCESSED      14 ITERATIONS                          12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           56 TO      504
PROJECTED ANSWERS:              33 TO      447

L3           12 SEA SSS SAM L1

=> dscan
DSCAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d scan
```

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C27 H31 F3 N8 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI)
MF C20 H13 Cl N6 . 2 C2 H F3 O2

CM 1



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2



L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C23 H16 F3 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Methanesulfonamide, N-[2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]ethyl]- (9CI)
MF C20 H19 Cl N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C26 H17 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-(1,1-dimethylethyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C21 H19 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazol-3-amine, N-[6,7-dihydro-2-[2-(trifluoromethyl)phenyl]-5H-cyclopentapyrimidin-4-yl]-5,7-difluoro- (9CI)
MF C21 H14 F5 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-ethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C19 H15 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Pyrido[3,2-d]pyrimidin-4-amine, 5,6,7,8-tetrahydro-N-1H-indazol-3-yl-5-(phenylmethyl)-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C28 H23 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-(9CI)
MF C21 H12 Cl2 F N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(4-fluoro-1H-indazol-3-yl)- (9CI)
MF C25 H22 F N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C23 H15 F4 N5 O
CI COM



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ALL ANSWERS HAVE BEEN SCANNED

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.84       1.05

STN INTERNATIONAL LOGOFF AT 16:30:33 ON 03 OCT 2004
```

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	5	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	12	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS	13	SEP 27	STANDARDS will no longer be available on STN
NEWS	14	SEP 27	SWETSCAN will no longer be available on STN
NEWS	15	SEP 30	STN downtime scheduled October 2-3, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:29:06 ON 03 OCT 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:29:12 ON 03 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2
DICTIONARY FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l1
NO L# DEFINED

There are no L# queries, structures, or screen sets
defined in the current session.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\STNEXP4\QUERIES\10632340.str



chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22
chain bonds :
4-13 6-7 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-18
15-16 15-19 16-17 16-22 17-18 19-20 20-21 21-22
exact/norm bonds :
4-13 6-7 13-14 14-15 14-18 15-16 15-19 16-17 16-22 17-18 19-20 20-21
21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:29:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     14 TO ITERATE

100.0% PROCESSED      14 ITERATIONS                          12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           56 TO      504
PROJECTED ANSWERS:              33 TO      447

L3           12 SEA SSS SAM L1

=> dscan
DSCAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d scan
```

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C27 H31 F3 N8 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI)
MF C20 H13 Cl N6 . 2 C2 H F3 O2

CM 1



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2



L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C23 H16 F3 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Methanesulfonamide, N-[2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]ethyl]- (9CI)
MF C20 H19 Cl N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C26 H17 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-(1,1-dimethylethyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C21 H19 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Indazol-3-amine, N-[6,7-dihydro-2-[2-(trifluoromethyl)phenyl]-5H-cyclopentapyrimidin-4-yl]-5,7-difluoro- (9CI)
MF C21 H14 F5 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-ethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C19 H15 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Pyrido[3,2-d]pyrimidin-4-amine, 5,6,7,8-tetrahydro-N-1H-indazol-3-yl-5-(phenylmethyl)-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C28 H23 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI)
MF C21 H12 Cl2 F N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(4-fluoro-1H-indazol-3-yl)- (9CI)
MF C25 H22 F N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI)
MF C23 H15 F4 N5 O
CI COM



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ALL ANSWERS HAVE BEEN SCANNED

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.84       1.05

STN INTERNATIONAL LOGOFF AT 16:30:33 ON 03 OCT 2004



Welcome to STN International!  Enter x:x

LOGINID:sssptal611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  Jul 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS  4  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS  5  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS  6  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available
 NEWS  7  AUG 27   BIOCOMMERCE: Changes and enhancements to content coverage
 NEWS  8  AUG 27   BIOTECHABS/BIOTECHDS: Two new display fields added for legal
                   status data from INPADOC
 NEWS  9  SEP 01   INPADOC: New family current-awareness alert (SDI) available
 NEWS 10  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS 11  SEP 01   New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS 12  SEP 14   STN Patent Forum to be held October 13, 2004, in Iselin, NJ
 NEWS 13  SEP 27   STANDARDS will no longer be available on STN
 NEWS 14  SEP 27   SWETSCAN will no longer be available on STN
 NEWS 15  SEP 30   STN downtime scheduled October 2-3, 2004

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
```

```
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:32:36 ON 03 OCT 2004

=> ile reg
ILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    0.21        0.21

FILE 'REGISTRY' ENTERED AT 16:32:45 ON 03 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 OCT 2004  HIGHEST RN 755753-81-2
DICTIONARY FILE UPDATES:   1 OCT 2004  HIGHEST RN 755753-81-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\STNEXP4\QUERIES\10632340-2.str
```



chain nodes :
13 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22
chain bonds :
3-25 4-13 6-7 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-18
15-16 15-19 16-17 16-22 17-18 19-20 20-21 21-22
exact/norm bonds :
3-25 4-13 6-7 13-14 14-15 14-18 15-16 15-19 16-17 16-22 17-18 19-20
20-21 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 :

G1:C,N

G2:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 25:CLASS

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l1

```
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:33:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     14 TO ITERATE

100.0% PROCESSED      14 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           56 TO      504
PROJECTED ANSWERS:               4 TO      200

L3            4 SEA SSS SAM L1

=> d scan
```

L3 4 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Methanesulfonamide, N-[2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]ethyl]- (9CI)
MF C20 H19 Cl N6 O2 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 4 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-ethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C19 H15 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 4 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C27 H31 F3 N8 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L3 4 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-(1,1-dimethylethyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
MF C21 H19 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l1 sss ful
FULL SEARCH INITIATED 16:33:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    304 TO ITERATE

100.0% PROCESSED     304 ITERATIONS                          76 ANSWERS
SEARCH TIME: 00.00.01

L4           76 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.42     155.63

FILE 'CAPLUS' ENTERED AT 16:33:34 ON 03 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 3 Oct 2004  VOL 141 ISS 15
FILE LAST UPDATED: 1 Oct 2004  (20041001/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l4
L5           9 L4

=> d l5 1-9 bib hitstr
```

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:120855 CAPLUS
DN 140:163888
TI Preparation of (pyrimidinyl)(pyrazolo[3,4-b]pyridinyl)amines and analogs as GSK-3 inhibitors
IN Forster, Cornelia J.; Park, Larry C.; Wannamaker, Marion W.; Yao, Yung-Mae
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004013140	A1	20040212	WO 2003-US23950	20030731
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004039007	A1	20040226	US 2003-632340	20030801
PRAI	US 2002-400967P	P	20020802		

OS MARPAT 140:163888
IT **656813-97-7P**, [6-(But-3-enyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(GKS-3 inhibitor; preparation of (pyrimidinyl)(pyrazolo[3,4-b]pyridinyl)amines and analogs as GSK-3 inhibitors)
RN 656813-97-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-(3-butenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT **656813-84-2P**, (5-Fluoro-1H-indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **656813-87-5P**, [6-tert-Butyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656813-92-2P**, [6-Cyclopropyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **656813-93-3P**, [6-Cyclopropyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656813-94-4P**,

[6-Cyclopropyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine hydrochloride **656813-98-8P**, [6-[3-(Morpholin-4-yl)propyl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656813-99-9P**, [6-[3-(Piperidin-1-yl)propyl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-00-5P**, [6-(3-Diethylaminopropyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-01-6P**, [6-[3-(4-Methylpiperazin-1-yl)propyl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-02-7P**, [6-[3-(Piperazin-1-yl)propyl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-03-8P**, [6-(3-Dimethylaminopropyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-04-9P**, N,N-Dimethyl-N'-[3-[6-[(1H-pyrazolo[3,4-b]pyridin-3-yl)amino]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]propyl]ethane-1,2-diamine **656814-05-0P**, [6-(3-Methylaminopropyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-06-1P**, 2-[[3-[6-[(1H-Pyrazolo[3,4-b]pyridin-3-yl)amino]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]propyl]amino]ethanol **656814-07-2P**, [6-[3-[[2-(Morpholin-4-yl)ethyl]amino]propyl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-08-3P**, [6-[3-[Methyl[2-(morpholin-4-yl)ethyl]amino]propyl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-pyrazolo[3,4-b]pyridin-3-yl)amine **656814-09-4P 656814-10-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GKS-3 inhibitor; preparation of (pyrimidinyl)(pyrazolo[3,4-b]pyridinyl)amines and analogs as GSK-3 inhibitors)

RN 656813-84-2 CAPLUS
CN 1H-Indazol-3-amine, 5-fluoro-N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 656813-87-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-(1,1-dimethylethyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656813-92-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclopropyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656813-93-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-cyclopropyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656813-94-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-cyclopropyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656813-98-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(4-morpholinyl)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656813-99-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(1-piperidinyl)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-00-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(diethylamino)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-01-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(4-methyl-1-piperazinyl)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-02-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(1-piperazinyl)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-03-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(dimethylamino)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-04-9 CAPLUS
CN 1,2-Ethanediamine, N,N-dimethyl-N'-[3-[6-(1H-pyrazolo[3,4-b]pyridin-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]propyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-05-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-(methylamino)propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-06-1 CAPLUS
CN Ethanol, 2-[[3-[6-(1H-pyrazolo[3,4-b]pyridin-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]propyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-07-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-[[2-(4-morpholinyl)ethyl]amino]propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-08-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-09-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, 5-fluoro-N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 656814-10-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-3-amine, N-[6-ethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220584 CAPLUS
DN 136:247584
TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Knegtel, Ronald; Golec, Julian M. C.; Li, Pan; Davies, Robert; Charrier, Jean-Damien
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 356 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022608	A1	20020321	WO 2001-US42152	20010914
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001096871	A5	20020326	AU 2001-96871	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1317452	A1	20030611	EP 2001-977779	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	JP 2004509118	T2	20040325	JP 2002-526861	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T2	20040624	JP 2002-565976	20011219
	JP 2004519479	T2	20040702	JP 2002-567928	20011219
	ZA 2003001697	A	20040301	ZA 2003-1697	20030228
	ZA 2003001699	A	20040301	ZA 2003-1699	20030228
	ZA 2003001702	A	20040301	ZA 2003-1702	20030228
	ZA 2003001704	A	20040301	ZA 2003-1704	20030228
	ZA 2003001698	A	20040302	ZA 2003-1698	20030228

	NO 2003001188	A	20030513	NO 2003-1188	20030314
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US42152	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247584

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220583 CAPLUS
DN 136:247583
TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Davies, Robert; Bebbington, David; Knegtel, Ronald; Wannamaker, Marion; Li, Pan; Forester, Cornelia; Pierce, Albert; Kay, David
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 373 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022607	A1	20020321	WO 2001-US28940	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001091013	A5	20020326	AU 2001-91013	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
BR 2001014088	A	20030617	BR 2001-14088	20010914
EP 1318997	A1	20030618	EP 2001-971082	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509117	T2	20040325	JP 2002-526860	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
EP 1345922	A1	20030924	EP 2001-271061	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228

	ZA 2003001698	A	20040302	ZA 2003-1698	20030228
	NO 2003001191	A	20030513	NO 2003-1191	20030314
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US28940	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247583

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404872-79-3P**
404872-80-6P 404872-81-7P 404872-82-8P
404872-83-9P 404872-84-0P 404872-85-1P
404872-86-2P 404872-87-3P 404873-06-9P
404873-07-0P 404873-08-1P 404873-09-2P
404873-10-5P 404873-11-6P 404873-12-7P
404873-13-8P 404873-14-9P 404873-15-0P
404873-16-1P 404873-17-2P 404873-18-3P
404873-19-4P 404873-20-7P 404873-21-8P
404873-22-9P 404873-23-0P 404873-24-1P
404873-25-2P 404873-26-3P 404873-27-4P
404873-28-5P 404873-29-6P 404873-30-9P
404873-32-1P 404873-33-2P 404873-36-5P

404873-37-6P 404873-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS
CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-79-3 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-aminocyclohexyl)-5-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-80-6 CAPLUS
CN Acetamide, N-[4-[6-(1H-indazol-3-ylamino)-5-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-81-7 CAPLUS
CN Methanesulfonamide, N-[4-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-

methyl-4-pyrimidinyl]cyclohexyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-82-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5-methyl-6-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-83-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5-methyl-6-(1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-84-0 CAPLUS
CN Piperazine, 1-acetyl-4-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-85-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl-4-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-86-2 CAPLUS
CN Piperazine, 1-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl-4-pyrimidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404872-87-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-methyl-1-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-06-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-07-0 CAPLUS
CN Piperidine, 2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-08-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-methyl-, phenylmethyl ester

(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-09-2 CAPLUS
CN Piperazine, 1-acetyl-3-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-10-5 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-11-6 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(1-methyl-2-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-12-7 CAPLUS
CN Acetamide, N-[2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-13-8 CAPLUS
CN Methanesulfonamide, N-[2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-14-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-aminocyclohexyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-15-0 CAPLUS
CN Carbamic acid, [2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-16-1 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-aminoethyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-17-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-piperidinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-18-3 CAPLUS
CN Acetamide, N-[2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-19-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-20-7 CAPLUS
CN Piperidine, 1-acetyl-4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-21-8 CAPLUS
CN Methanesulfonamide, N-[2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-22-9 CAPLUS
CN Piperidine, 1-acetyl-2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-23-0 CAPLUS
CN Piperidine, 2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-24-1 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-25-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(1-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-26-3 CAPLUS
CN Piperazine, 1-acetyl-4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-27-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-28-5 CAPLUS
CN Piperazine, 1-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-29-6 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-methyl-1-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-30-9 CAPLUS
CN 4-Pyrimidinecarbonitrile, 6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-32-1 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(1H-imidazol-4-yl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-33-2 CAPLUS
CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-36-5 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenoxy-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-37-6 CAPLUS
CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N'-(5,7-difluoro-1H-indazol-3-yl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404873-38-7 CAPLUS
CN 4-Pyrimidinesulfonamide, 2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220582 CAPLUS
DN 136:247582
TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Binch, Hayley; Knegtel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 355 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022606	A1	20020321	WO 2001-US28803	20010914
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090944	A5	20020326	AU 2001-90944	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1317448	A1	20030611	EP 2001-971006	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	JP 2004509116	T2	20040325	JP 2002-526859	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T2	20040624	JP 2002-565976	20011219
	JP 2004519479	T2	20040702	JP 2002-567928	20011219
	ZA 2003001697	A	20040301	ZA 2003-1697	20030228
	ZA 2003001699	A	20040301	ZA 2003-1699	20030228
	ZA 2003001702	A	20040301	ZA 2003-1702	20030228
	ZA 2003001704	A	20040301	ZA 2003-1704	20030228

	ZA 2003001698	A	20040302	ZA 2003-1698	20030228
	NO 2003001189	A	20030513	NO 2003-1189	20030314
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US28803	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247582

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4- pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4- pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220581 CAPLUS
DN 136:247581
TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Golec, Julian M. C.; Charrier, Jean-Damien; Knegtel, Ronald; Bebbington, David; Davies, Robert; Li, Pan
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 357 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022605	A1	20020321	WO 2001-US28793	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001092670	A5	20020326	AU 2001-92670	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
EP 1317449	A1	20030611	EP 2001-973050	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509115	T2	20040325	JP 2002-526858	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
EP 1345922	A1	20030924	EP 2001-271061	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228

	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US28793	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247581

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4- pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4- pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220580 CAPLUS
DN 136:247606
TI Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease.
IN Davies, Robert; Bebbington, David; Binch, Haley; Knegtel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 357 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022604	A1	20020321	WO 2001-US28792	20010914
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001094558	A5	20020326	AU 2001-94558	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1317450	A1	20030611	EP 2001-975210	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	JP 2004512277	T2	20040422	JP 2002-526857	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T2	20040624	JP 2002-565976	20011219
	JP 2004519479	T2	20040702	JP 2002-567928	20011219
	ZA 2003001697	A	20040301	ZA 2003-1697	20030228
	ZA 2003001699	A	20040301	ZA 2003-1699	20030228
	ZA 2003001702	A	20040301	ZA 2003-1702	20030228

	ZA 2003001704	A	20040301	ZA 2003-1704	20030228
	ZA 2003001698	A	20040302	ZA 2003-1698	20030228
	NO 2003001190	A	20030513	NO 2003-1190	20030314
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US28792	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247606

IT **404826-46-6P 404826-47-7P 404826-48-8P**
404826-49-9P 404826-50-2P 404826-51-3P
404826-52-4P 404826-53-5P 404826-54-6P
404826-55-7P 404826-56-8P 404826-57-9P
404826-58-0P 404826-59-1P 404827-52-7P
404827-53-8P 404829-53-4P 404829-79-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-47-7 CAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220579 CAPLUS
DN 136:247580
TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Davies, Robert; Li, Pan; Golec, Julian; Bebbington, David
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 406 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022603	A1	20020321	WO 2001-US28738	20010914
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090912	A5	20020326	AU 2001-90912	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1317447	A1	20030611	EP 2001-970969	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	JP 2004525075	T2	20040819	JP 2002-526856	20010914
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T2	20040624	JP 2002-565976	20011219
	JP 2004519479	T2	20040702	JP 2002-567928	20011219
	ZA 2003001697	A	20040301	ZA 2003-1697	20030228
	ZA 2003001699	A	20040301	ZA 2003-1699	20030228
	ZA 2003001702	A	20040301	ZA 2003-1702	20030228
	ZA 2003001704	A	20040301	ZA 2003-1704	20030228
	ZA 2003001698	A	20040302	ZA 2003-1698	20030228
	NO 2003002704	A	20030821	NO 2003-2704	20030613

	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US28738	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247580

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-
pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-
pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220578 CAPLUS
DN 136:263164
TI Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Knegtel, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 377 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022602	A2	20020321	WO 2001-US42162	20010914
	WO 2002022602	A3	20020627		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001096875	A5	20020326	AU 2001-96875	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1318814	A2	20030618	EP 2001-977783	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	JP 2004509114	T2	20040325	JP 2002-526855	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T2	20040624	JP 2002-565976	20011219
	JP 2004519479	T2	20040702	JP 2002-567928	20011219
	ZA 2003001697	A	20040301	ZA 2003-1697	20030228
	ZA 2003001699	A	20040301	ZA 2003-1699	20030228
	ZA 2003001702	A	20040301	ZA 2003-1702	20030228
	ZA 2003001704	A	20040301	ZA 2003-1704	20030228

	ZA 2003001698	A	20040302	ZA 2003-1698	20030228
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US42162	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:263164

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220577 CAPLUS
DN 136:247579
TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
IN Knegtel, Ronald; Bebbington, David; Binch, Hayley; Golec, Julian; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 376 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022601	A1	20020321	WO 2001-US28740	20010914
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090914	A5	20020326	AU 2001-90914	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1317444	A1	20030611	EP 2001-970971	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	JP 2004509113	T2	20040325	JP 2002-526854	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T2	20040624	JP 2002-565976	20011219
	JP 2004519479	T2	20040702	JP 2002-567928	20011219
	ZA 2003001697	A	20040301	ZA 2003-1697	20030228
	ZA 2003001699	A	20040301	ZA 2003-1699	20030228
	ZA 2003001702	A	20040301	ZA 2003-1702	20030228
	ZA 2003001704	A	20040301	ZA 2003-1704	20030228

	ZA 2003001698	A	20040302	ZA 2003-1698	20030228
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	US 2004116454	A1	20040617	US 2003-692355	20031023
	US 2004157893	A1	20040812	US 2003-722374	20031125
	US 2004132781	A1	20040708	US 2003-736426	20031215
	US 2004167141	A1	20040826	US 2004-775699	20040210
PRAI	US 2000-232795P	P	20000915		
	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2001-955601	A3	20010914		
	WO 2001-US28740	W	20010914		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 136:247579

IT **404826-46-6P**, (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-47-7P**, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-48-8P**, (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-49-9P**, (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-50-2P**, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-51-3P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404826-52-4P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-53-5P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404826-54-6P**, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-55-7P**, (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine **404826-56-8P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404826-57-9P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine **404826-58-0P**, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine **404826-59-1P**, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine **404827-52-7P**, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404827-53-8P**, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine **404829-53-4P**, (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine **404829-79-4P**, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-46-6 CAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-47-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-48-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-49-9 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-50-2 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-51-3 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-52-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-53-5 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-54-6 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-55-7 CAPLUS
CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-56-8 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-57-9 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-58-0 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404826-59-1 CAPLUS
CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-52-7 CAPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-53-8 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-53-4 CAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404829-79-4 CAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              29.87     185.50

STN INTERNATIONAL LOGOFF AT 16:34:00 ON 03 OCT 2004
```